Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial of enfortumab vedotin plus pembrolizumab in urothelial carcinoma.
Oncology Unplugged With Dr Chandler Park
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
4
Dostarlimab Monotherapy Elicits Responses in First-Line PD-L1-Positive HNSCC
5